Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Effect of Physical Activity on Mortality and Cardiovascular Disease in 130 000 People From 17 High-Income, Middle-Income, and Low-Income Countries: The Pure Study Publisher Pubmed



Lear SA1 ; Hu W2 ; Rangarajan S2 ; Gasevic D3 ; Leong D2 ; Iqbal R4 ; Casanova A2 ; Swaminathan S5 ; Anjana RM6 ; Kumar R7 ; Rosengren A8 ; Wei L9 ; Yang W9 ; Chuangshi W9 Show All Authors
Authors
  1. Lear SA1
  2. Hu W2
  3. Rangarajan S2
  4. Gasevic D3
  5. Leong D2
  6. Iqbal R4
  7. Casanova A2
  8. Swaminathan S5
  9. Anjana RM6
  10. Kumar R7
  11. Rosengren A8
  12. Wei L9
  13. Yang W9
  14. Chuangshi W9
  15. Huaxing L10
  16. Nair S11
  17. Diaz R12
  18. Swidon H13
  19. Gupta R14
  20. Mohammadifard N15
  21. Lopezjaramillo P16
  22. Oguz A17
  23. Zatonska K18
  24. Seron P19
  25. Avezum A20
  26. Poirier P21
  27. Teo K2
  28. Yusuf S2

Source: The Lancet Published:2017


Abstract

Background Physical activity has a protective effect against cardiovascular disease (CVD) in high-income countries, where physical activity is mainly recreational, but it is not known if this is also observed in lower-income countries, where physical activity is mainly non-recreational. We examined whether different amounts and types of physical activity are associated with lower mortality and CVD in countries at different economic levels. Methods In this prospective cohort study, we recruited participants from 17 countries (Canada, Sweden, United Arab Emirates, Argentina, Brazil, Chile, Poland, Turkey, Malaysia, South Africa, China, Colombia, Iran, Bangladesh, India, Pakistan, and Zimbabwe). Within each country, urban and rural areas in and around selected cities and towns were identified to reflect the geographical diversity. Within these communities, we invited individuals aged between 35 and 70 years who intended to live at their current address for at least another 4 years. Total physical activity was assessed using the International Physical Activity Questionnaire (IPQA). Participants with pre-existing CVD were excluded from the analyses. Mortality and CVD were recorded during a mean of 6·9 years of follow-up. Primary clinical outcomes during follow-up were mortality plus major CVD (CVD mortality, incident myocardial infarction, stroke, or heart failure), either as a composite or separately. The effects of physical activity on mortality and CVD were adjusted for sociodemographic factors and other risk factors taking into account household, community, and country clustering. Findings Between Jan 1, 2003, and Dec 31, 2010, 168 916 participants were enrolled, of whom 141 945 completed the IPAQ. Analyses were limited to the 130 843 participants without pre-existing CVD. Compared with low physical activity (<600 metabolic equivalents [MET] × minutes per week or <150 minutes per week of moderate intensity physical activity), moderate (600–3000 MET × minutes or 150–750 minutes per week) and high physical activity (>3000 MET × minutes or >750 minutes per week) were associated with graded reduction in mortality (hazard ratio 0·80, 95% CI 0·74–0·87 and 0·65, 0·60–0·71; p<0·0001 for trend), and major CVD (0·86, 0·78–0·93; p<0·001 for trend). Higher physical activity was associated with lower risk of CVD and mortality in high-income, middle-income, and low-income countries. The adjusted population attributable fraction for not meeting the physical activity guidelines was 8·0% for mortality and 4·6% for major CVD, and for not meeting high physical activity was 13·0% for mortality and 9·5% for major CVD. Both recreational and non-recreational physical activity were associated with benefits. Interpretation Higher recreational and non-recreational physical activity was associated with a lower risk of mortality and CVD events in individuals from low-income, middle-income, and high-income countries. Increasing physical activity is a simple, widely applicable, low cost global strategy that could reduce deaths and CVD in middle age. Funding Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Ontario SPOR Support Unit, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, GSK, Novartis, King Pharma, and national and local organisations in participating countries that are listed at the end of the Article. © 2017 Elsevier Ltd
Other Related Docs